Nyrada Unveils Target of its Brain Injury Program as TRPC Ion Channels & Provides Phase I Study Update

• Brain Injury Program target revealed as versatile TRPC ion channels
• NYR-BI02 is a potent blocker of three TRPC ion channel subtypes, limiting excitotoxicity
• Patent application filed to protect Nyrada’s technology
• No FDA-approved drug exists to treat secondary brain injury
• Potential to pursue multiple additional diseases involving TRPC ion channels, including further neurological diseases and diseases of the kidneys, heart, lung, and muscle
• Pending manufacturing and ethics committee approval, recruitment of patients into the Phase I traumatic brain injury trial is expected to commence in 2H CY2022 in Australia